Physician profile
Myrtle Jeroudi
NPI 1588922975
$2,033.84
in general payments reported to CMS, 2019-2025
28 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $373 · 2021: $357 · 2022: $360 · 2024: $22.07 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274 · Consulting Fee: $200 · Education: $72.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.37 |
| Consulting Fee | $200.00 |
| Education | $72.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $404.82 | 2024-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $203.29 | 2019-2025 | |
| Abbvie INC. | $198.98 | 2021-2022 | |
| Allergan, INC. | $187.48 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $142.94 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $128.91 | 2019-2021 | |
| Harmony Biosciences LLC | $83.07 | 2020-2025 | |
| Csl Behring | $72.14 | 2019-2020 | |
| Amgen INC. | $66.41 | 2019-2021 | |
| Biogen, INC. | $58.15 | 2019-2021 | |
| Emd Serono, INC. | $48.13 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $46.46 | 2021 | |
| Acorda Therapeutics, INC | $43.42 | 2019 | |
| Livanova USA, INC. | $40.68 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $37.15 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $36.53 | 2020 | |
| Merz Pharmaceuticals, LLC | $36.41 | 2021 | |
| Shire North American Group INC | $23.16 | 2019 | |
| Owp Pharmaceuticals, INC. | $21.22 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.81 | 2022 | |
| Kyowa Kirin, INC. | $20.49 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.80 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.01 | 2019 | |
| Grifols USA, LLC | $17.00 | 2019 | |
| Currax Pharmaceuticals LLC | $16.54 | 2020 | |
| Impel Pharmaceuticals INC. | $16.23 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.25 | 2022 | |
| Almatica Pharma LLC | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myrtle Jeroudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.